On March 31, 2019 F1 Oncology, Inc., a biotechnology company discovering and developing adoptive cellular therapies (ACTs) for solid tumors, reported that it will present four abstracts at the American Association of Cancer Research (AACR) (Free AACR Whitepaper) 2019 Annual Meeting in Atlanta from March 29-April 3, 2019 that support novel technologies to treat solid tumor malignancies (Press release, F1 Oncology, MAR 31, 2019, View Source [SID1234534788]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
F1 Oncology is developing these novel CAB-CAR-T therapies to target solid tumors while minimizing the potential of on-target, off-tumor activity. The four abstracts provide insight into the use of the company’s proprietary CAB-CAR-T technology to increase the potential safety of CAR-T therapeutics by turning the negative effects of the tumor microenvironment (TME) into activating signals. They will highlight proof of concept studies of same-day, point of care CAR-T and use bioinformatics data driven methods to discover protein domain combinations capable of selectively expanding CAR-T cells.
"The data to be presented highlight scientific progress that may greatly simplify CAR-T therapy for solid tumor malignancies in the future," said Gregory Frost, Ph.D., Chairman and CEO of F1 Oncology. "The teams have also made significant progress in our understanding of CAB-CAR-T’s role in adoptive cellular therapy for solid tumors, and we look forward to seeing the progress from ongoing clinical studies with these programs through collaborators in Shanghai."
The abstracts are available in the program section of the annual AACR (Free AACR Whitepaper) meeting website, and details for the poster presentations are as follows:
Same day transduction and in vivo expansion of chimeric antigen receptors and synthetic driver constructs for adoptive cellular therapy
Examining the relationship between limiting the ex vivo expansion time and less differentiated CAR-T products with enhanced effector function, as well as the development of a point of care approach to ACT and its potential to reduce the complexity of CAR-T cell immunotherapy.
Poster Board Number: Session PO.IM02.03 2327/26
Session Date and Time: April 1, 2019, 1:00 p.m. – 5:00 p.m.
Location: Georgia World Conference Center, Poster Section 22
A high-throughput screening strategy for the identification of novel lymphoproliferative elements
Examining a high throughput screening method using a barcoded high-diversity combinatorial library of various rationally-designed protein subdomains to identify novel combinations capable of selectively driving CAR-T cells in vivo.
Poster Board Number: Session PO.MCB09.05 3523/9
Session Date and Time: April 2, 2019, 8:00 a.m. – 12:00 p.m.
Location: Georgia World Conference Center, Poster Section 22
CAB-CAR-T: A novel conditionally active biologics approach to minimize on-target off-tumor effects in adoptive immunotherapy
Describing a novel Conditionally Active Biologics (CAB) approach in adoptive immunotherapy
Poster Board Number: session PO.IM02.04 3189/12
Session Date and Time: April 2, 2019, 8:00 a.m. – 12:00 p.m.
Location: Georgia World Conference Center, Poster Section 22
CAB-CAR-T: The Prioritization of Cell Surface Protein Targets for Conditionally Active Biologics to Treat All Solid Tumors
Identifying optimal targets across all TCGA cancer cohorts that when used in CAB-CAR-T therapies will provide the greatest number of treatment options for patients across all cancer malignancies.
Poster Board Number: Session PO.BSB01.05 5101/9
Session Date and Time: April 3, 2019, 8:00 a.m. – 12:00 p.m.
Location: Georgia World Conference Center, Poster Section 30